within Pharmacolibrary.Drugs.ATC.N;

model N07XX05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.93,
    Cl             = 0.6333333333333333,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.0026,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004166666666666667,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Amifampridine (3,4-diaminopyridine) is a potassium channel blocker used primarily in the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. It is also investigated in other disorders with neuromuscular transmission impairment. The drug is currently approved in the US and EU for use in LEMS.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with LEMS, both sexes, following oral administration as immediate-release formulation.</p><h4>References</h4><ol><li><p>Haroldsen, PE, et al., &amp; O&#x27;Neill, CA (2015). Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults. <i>Clinical therapeutics</i> 37(7) 1555–1563. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2015.05.498&quot;>10.1016/j.clinthera.2015.05.498</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26101174/&quot;>https://pubmed.ncbi.nlm.nih.gov/26101174</a></p></li><li><p>Ishida, N, et al., &amp; Komai, K (2015). Pharmacokinetics and safety of 3,4-diaminopyridine base in healthy Japanese volunteers. <i>International journal of clinical pharmacology and therapeutics</i> 53(8) 674–680. DOI:<a href=&quot;https://doi.org/10.5414/CP202133&quot;>10.5414/CP202133</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26152130/&quot;>https://pubmed.ncbi.nlm.nih.gov/26152130</a></p></li><li><p>Harris, TL, et al., &amp; Janda, KD (2016). Lycopodium clavatum exine microcapsules enable safe oral delivery of 3,4-diaminopyridine for treatment of botulinum neurotoxin A intoxication. <i>Chemical communications (Cambridge, England)</i> 52(22) 4187–4190. DOI:<a href=&quot;https://doi.org/10.1039/c6cc00615a&quot;>10.1039/c6cc00615a</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26906286/&quot;>https://pubmed.ncbi.nlm.nih.gov/26906286</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N07XX05;
